106 related articles for article (PubMed ID: 18381942)
1. 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
Na II; Byun BH; Kang HJ; Cheon GJ; Koh JS; Kim CH; Choe DH; Ryoo BY; Lee JC; Lim SM; Yang SH
Clin Cancer Res; 2008 Apr; 14(7):2036-41. PubMed ID: 18381942
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
3. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
[TBL] [Abstract][Full Text] [Related]
4. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Lee KH; Lee SH; Kim DW; Kang WJ; Chung JK; Im SA; Kim TY; Kim YW; Bang YJ; Heo DS
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4232-6. PubMed ID: 16857796
[TBL] [Abstract][Full Text] [Related]
5. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Keam B; Lee SJ; Kim TM; Paeng JC; Lee SH; Kim DW; Jeon YK; Chung DH; Kang KW; Chung JK; Heo DS
J Thorac Oncol; 2015 Aug; 10(8):1189-94. PubMed ID: 26200273
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
Na II; Byun BH; Kim KM; Cheon GJ; Choe du H; Koh JS; Lee DY; Ryoo BY; Baek H; Lim SM; Yang SH; Kim CH; Lee JC
Lung Cancer; 2010 Jan; 67(1):76-80. PubMed ID: 19371962
[TBL] [Abstract][Full Text] [Related]
8. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
Sasaki R; Komaki R; Macapinlac H; Erasmus J; Allen P; Forster K; Putnam JB; Herbst RS; Moran CA; Podoloff DA; Roth JA; Cox JD
J Clin Oncol; 2005 Feb; 23(6):1136-43. PubMed ID: 15718309
[TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Riely GJ; Kris MG; Zhao B; Akhurst T; Milton DT; Moore E; Tyson L; Pao W; Rizvi NA; Schwartz LH; Miller VA
Clin Cancer Res; 2007 Sep; 13(17):5150-5. PubMed ID: 17785570
[TBL] [Abstract][Full Text] [Related]
10. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Takahashi R; Hirata H; Tachibana I; Shimosegawa E; Inoue A; Nagatomo I; Takeda Y; Kida H; Goya S; Kijima T; Yoshida M; Kumagai T; Kumanogoh A; Okumura M; Hatazawa J; Kawase I
Clin Cancer Res; 2012 Jan; 18(1):220-8. PubMed ID: 22019513
[TBL] [Abstract][Full Text] [Related]
11. Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results.
Hamamoto Y; Sugawara Y; Inoue T; Kataoka M; Ochi T; Takahashi T; Sakai S
Jpn J Clin Oncol; 2011 Apr; 41(4):543-7. PubMed ID: 21262874
[TBL] [Abstract][Full Text] [Related]
12. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer.
Furukawa T; Miyata Y; Kushitani K; Mimae T; Tsutani Y; Takeshima Y; Okada M
Jpn J Clin Oncol; 2015 Dec; 45(12):1154-61. PubMed ID: 26386467
[TBL] [Abstract][Full Text] [Related]
13. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Glut-1 glucose transporter expression with.
Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
16. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
Downey RJ; Akhurst T; Gonen M; Vincent A; Bains MS; Larson S; Rusch V
J Clin Oncol; 2004 Aug; 22(16):3255-60. PubMed ID: 15310769
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.
de Jong WK; van der Heijden HF; Pruim J; Dalesio O; Oyen WJ; Groen HJ
J Thorac Oncol; 2007 Nov; 2(11):1007-12. PubMed ID: 17975491
[TBL] [Abstract][Full Text] [Related]
18. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
Sohn HJ; Yang YJ; Ryu JS; Oh SJ; Im KC; Moon DH; Lee DH; Suh C; Lee JS; Kim SW
Clin Cancer Res; 2008 Nov; 14(22):7423-9. PubMed ID: 19010859
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
